Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Apple Turns 50: From Garage Startup to AI Crossroads 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
AUSTIN, Texas, Aug. 31, 2017 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that management will be presenting at the 2017 Wells Fargo Healthcare Conference in Boston on Wednesday, September 6 at 8:30 a.m. ET.
To access the live and archived webcast of the presentation, please visit the Investor Relations section of the Aeglea BioTherapeutics website. The webcast and presentation will be archived for viewing for 60 days thereafter.
About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company’s engineered human enzymes are designed to modulate the extremes of amino acid metabolism in the blood to reduce toxic levels of amino acids in inborn errors of metabolism or target tumor metabolism for cancer treatment. AEB1102, Aeglea’s lead product candidate, is currently being studied in two ongoing Phase 1 clinical trials in patients with advanced solid tumors and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Additionally, Aeglea is recruiting patients into its ongoing Phase 1/2 trial of AEB1102 for the treatment of patients with Arginase 1 Deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine, and its oxidized form cystine, and AEB2109, which degrades methionine.
For more information, please visit http://aegleabio.com.
Media Contact: Kelly Boothe, Ph.D. Pure Communications 415.946.1076 [email protected] Investor Contact: Charles N. York II Chief Financial Officer Aeglea BioTherapeutics [email protected]
